Your browser doesn't support javascript.
loading
The treatment effect across ASPECTS in acute ischemic stroke: Analysis from the AcT Trial.
Kaveeta, Chitapa; Alhabli, Ibrahim; Bala, Fouzi; Horn, MacKenzie; Benali, Faysal; Coutts, Shelagh B; Zafar, Atif; Bereznyakova, Olena; Khaw, Alexander V; Khosravani, Houman; Hunter, Gary R; Tkach, Aleksander; Dowlatshahi, Dar; Catanese, Luciana; Bogiatzi, Chrysi; Appireddy, Ramana; Buck, Brian; Swartz, Richard H; Sajobi, Tolulope; Almekhlafi, Mohammed; Demchuk, Andrew M; Ganesh, Aravind; Menon, Bijoy K; Singh, Nishita.
Afiliación
  • Kaveeta C; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Alhabli I; Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Bala F; Department of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Horn M; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Benali F; Diagnostic and Interventional Neuroradiology Department, University Hospital of Tours, Tours, France.
  • Coutts SB; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Zafar A; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Bereznyakova O; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Khaw AV; Department of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Khosravani H; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Hunter GR; St Michael's Hospital, Division of Vascular Neurology, Department of Medicine, University of Toronto, Ontario, Canada.
  • Tkach A; Department of Clinical Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
  • Dowlatshahi D; London Health Sciences Center and Western University, London, Ontario, Canada.
  • Catanese L; Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Bogiatzi C; Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Appireddy R; Department of Neuroscience, Kelowna General Hospital, Kelowna, British Columbia, Canada.
  • Buck B; Department of Medicine, University of Ottawa and the Ottawa Heart Research Institute, Ottawa, Ontario, Canada.
  • Swartz RH; Hamilton Health Sciences Centre and McMaster University, Hamilton, Ontario, Canada.
  • Sajobi T; London Health Sciences Center and Western University, London, Ontario, Canada.
  • Almekhlafi M; Division of Neurology, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Demchuk AM; Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Ganesh A; Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Menon BK; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Singh N; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Int J Stroke ; : 17474930241273561, 2024 Jul 31.
Article en En | MEDLINE | ID: mdl-39086232
ABSTRACT

BACKGROUND:

Early ischemic changes on baseline imaging are commonly evaluated for acute stroke decision-making and prognostication.

AIMS:

We assess the association of early ischemic changes on clinical outcomes and whether it differs between intravenous tenecteplase versus Alteplase.

METHODS:

Data are from the phase 3, Alteplase compared to Tenecteplase (AcT) trial. Subjects with anterior circulation stroke were included. Early ischemic changes were assessed using the Alberta Stroke Program Early CT score (ASPECTS). Efficacy outcomes included modified Rankin scale (mRS) 0-1, mRS 0-2, and ordinal mRS at 90 days. Safety outcomes included 24-hour symptomatic intracerebral hemorrhage (sICH), any hemorrhage on follow-up scan, and 90-day mortality rate. Mixed effects logistic regression was used to assess the association of ASPECTS [continuous and categorical (0-4 vs. 5-7 vs. 8-10)] with outcomes and if these associations were modified by thrombolytic type after adjusting for age, sex, and baseline stroke severity.

RESULTS:

Of the 1577 patients in the trial, 901 patients (56.3%) (median age 75 years [IQR 65-84], 50.8% females, median NIHSS 14 [IQR 17-19]) with anterior circulation stroke were included. mRS 0-1 at 90d was achieved in 1/14 (0.3%), 43/160 (14.7%) and 252/726 (85.1%) in the ASPECTS 0-4, 5-7 and 8-10 groups respectively. Every 1-point decrease in ASPECTS was associated with 2.7% and 1.9% decrease in chances of mRS 0-1 and mRS 0-2 at 90 days, respectively, and 1.9% chances of increase in mortality at 90 days. Subgroup analysis in EVT treated population showed similar results. Thrombolytic type did not modify this association between ASPECTS and 90-day mRS 0-1 (P interaction 0.75). There was no significant interaction by thrombolytic type with any other outcome.

CONCLUSIONS:

Similar to prior studies, we found that every one-point decrease in ASPECTS was associated with poorer clinical and safety outcomes. This effect did not differ between alteplase and tenecteplase.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Stroke Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Stroke Año: 2024 Tipo del documento: Article País de afiliación: Canadá